Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic ...
1 day ago · In This Article: Total Revenue: $85 million for Q3 2024. Product Sales: $38 million for Q3 2024, compared to $2 million in Q3 2023. Cost of Sales: $61 million for Q3 2024, compared to $99 million ...
Novavax stock plunges after quarterly earnings, but company sees …
2 days ago · PFE. Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year. The company now expects $650 million to $700 million in ...
Novavax, Inc. (NVAX) Latest Stock News & Headlines - Yahoo …
Jul 1, 2022 · Get the latest Novavax, Inc. (NVAX) stock news and headlines to help you in your trading and investing decisions.
Novavax: FDA removes clinical hold on Covid-19/flu combo trial
3 days ago · Nov. 11, 2024, 07:35 AM. Novavax (NVAX) announced that the U.S. FDA has removed the clinical hold on Novavax’s Investigational New Drug application for its COVID-19-Influenza Combination and ...
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials
1d. N ovavax (NASDAQ: NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza ...
Novavax's Updated Protein-based COVID-19 Vaccine Now an …
GAITHERSBURG, Md., Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to ...
Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal - Bloomberg.com
May 10, 2024 · Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot.
Novavax shares soar on license deal with Sanofi at lofty valuation
May 10, 2024 · Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at double its ...
Press releases & statements | Novavax Investor Relations
Nov 4, 2024 · Stay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
Novavax Advances Vaccine Strategy Amid Financial Shifts
1 day ago · Novavax ( (NVAX)) has released its Q3 earnings. Here is a breakdown of the information Novavax presented to its investors. Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology ...
- Some results have been removed